Navigation Links
Lawsuit Alleging Actos Caused Arizona Man’s Bladder Cancer Filed by Parker Waichman LLP
Date:6/12/2013

New York, New York (PRWEB) June 12, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of an Arizona man who developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23, 2013 in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1235). It is one of thousands of cases that have been filed into the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff started taking Actos to treat his Type 2 diabetes in March 2003. By November 2008, he was diagnosed with bladder cancer, allegedly due to the side effects of Actos. Additionally, the suit alleges that the Defendants knew about the risk of bladder cancer but did not disclose this information to consumers in order to protect financial interests. The Plaintiff alleges that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk. (http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm)

Research supports the link between Actos and bladder cancer. Last May, a study in the British Medical Journal found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal found that patients taking the medication were 22 percent more likely to get bladder cancer. (http://www.bmj.com/content/344/bmj.e3645) (http://www.cmaj.ca/content/early/2012/07/03/cmaj.112102)

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/actos-bladdercancer/062013/prweb10827844.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. LawyersandSettlements.com Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
2. The Law Office of Wolf & Pravato, The Alters Firm and Morelli Ratner File Class Action Lawsuit Against Global Spray Foam Manufacturer
3. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
4. New Lawsuit Alleges Teen Molestation by Ex-Deputy
5. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
6. New Lawsuit on Propecia: Severe Adverse Events
7. New Lawsuit on Accutane Crohn’s Disease: Severe Adverse Events
8. New Lawsuit alleges Actos caused Bladder Cancer
9. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
10. Wright & Schulte File Skechers Lawsuit on Behalf of Ohio Woman Who Fell, Suffered Broken Wrist Allegedly Due to Use of Skechers Shape-Ups
11. Transvaginal Mesh Lawsuit Update: New Study Concerning Use of Vaginal Mesh in Prolapse Procedures, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... ... The Journal of Pain Research has published the commentary “ Terminology of ... Dr John F. Peppin says “Terminology matters, yet little attention has been paid to ... cancer pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... The guide will ensure lab personnel have a basic understanding of the techniques ... measurement protocols. Enhanced understanding will help them reduce waste and rework to create ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... cleaning and sealing company , is proud to announce that many of their ... levels of customer service. The hard surface restoration franchises received customer recognition through ...
(Date:2/8/2016)... PLAINSBORO, N.J. (PRWEB) , ... February 08, 2016 , ... ... on cancer patients, has officially launched the Multiple Myeloma Heroes Awards event , ... (MM) or in the lives of patients with MM. The MM Heroes Awards ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie ... celebrates the beginning of a new charity campaign. As part of their ongoing ... Advocates (CASA). In the belief that children deserve a voice, and in the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... its fiscal 2016 first quarter ended December 31, 2015. ... Fiscal 2016 First Quarter Highlights , Revenue of ... quarter of 2015 , Domestic Radiation Measurement services revenues ...
(Date:2/9/2016)... , February 9, 2016 ... QIA) gab heute den Abschluss eines Kooperationsvertrags ... Förderung umfassender Lösungen in den Bereichen Next-Generation-Sequencing ... QGEN ; Frankfurt Prime Standard: QIA) ... 10x Genomics für die Entwicklung und Förderung ...
(Date:2/9/2016)... Feb. 9, 2016 Mast Therapeutics, Inc. ... for sickle cell disease and heart failure, today announced that ... to purchase common stock in an underwritten public offering.  The ... can be no assurance as to whether or when the ... or terms of the offering.   --> ...
Breaking Medicine Technology: